Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
coxsackievirus a21
- Development stage
- Phase 2
- Lead developer
- Merck
- Modality
- Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Oncolytic Viruses → Oncolytic Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Intratumoral, Intravenous
01
Overview
Coxsackievirus A21 (CVA21) is a naturally occurring, nonenveloped RNA enterovirus developed as an oncolytic virus therapy for cancer. It selectively infects and lyses tumor cells by targeting the intercellular adhesion molecule 1 (ICAM-1) and decay-accelerating factor (DAF/CD55), which are overexpressed in several cancers including metastatic melanoma. Upon administration, the virus replicates within tumor cells leading to direct cell lysis and induction of antitumor immune responses. The most clinically advanced formulation is known as V937 or CAVATAK. Developed from the wild-type Kuykendall strain, it has been evaluated in clinical trials for unresectable melanoma and other solid tumors. The main mode of action involves viral infiltration and replication within tumors resulting in destruction of malignant tissue[1][3][5][6].
- Brand names
- CAVATAK
- Other names
- coxsackievirus A21CVA21CVA-21CVA 21V937V-937V 937
02
Targets
CD55 (Complement decay-accelerating factor)ICAM1 (Intercellular Adhesion Molecule 1)
Beyond the preview
Go deeper on coxsackievirus a21.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on coxsackievirus a21.